BCR and olfactory neuroblastoma: This review compared the results after OpS ± E-ass, stratified relative to BCR/TCR ± E-ass, CFR ± E-ass, and TFR ± E-ass, and ES for esthesioneuroblastoma selecting 144 reports including 1,434 patients published from 1990 to 2023.